Login to Your Account



ThromboGenics Extends Runway with $103.2M Raise

By Marie Powers
Staff Writer

Wednesday, April 4, 2012
Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of about 3.2 million new shares with domestic and international investors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription